{"id":"azacitidine-associated-with-idarubicine","safety":{"commonSideEffects":[{"rate":"50-70%","effect":"Myelosuppression"},{"rate":"30-50%","effect":"Nausea and vomiting"},{"rate":"20-40%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1489","moleculeType":"Small molecule","molecularWeight":"244.21"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Azacitidine works by inhibiting DNA methyltransferase enzymes, leading to hypomethylation of DNA and changes in gene expression. Idarubicin intercalates DNA strands, thereby inhibiting the synthesis of macromolecules and inducing apoptosis in cancer cells.","oneSentence":"Azacitidine is a DNA methyltransferase inhibitor, and Idarubicin is an anthracycline antibiotic that intercalates DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:30:16.119Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia"}]},"trialDetails":[{"nctId":"NCT00801489","phase":"PHASE2","title":"Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-04-04","conditions":"Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1","enrollment":270},{"nctId":"NCT01342692","phase":"PHASE2","title":"Best Promising Drug Association With Azacitidine in Higher Risk Myelodysplastic Syndromes","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2011-06","conditions":"MDS","enrollment":320}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Azacitidine associated with Idarubicine","genericName":"Azacitidine associated with Idarubicine","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Azacitidine is a DNA methyltransferase inhibitor, and Idarubicin is an anthracycline antibiotic that intercalates DNA. Used for Acute myeloid leukemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}